Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration (wAMD)

NCT03558074 is registered in ClinicalTrials.gov with Alkahest, Inc. as lead sponsor.

NCT NCT03558074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration (wAMD)
Lead sponsor
Alkahest, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 20, 2018
Completion date
November 29, 2018
Enrollment
26 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration